Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Neoplasia (New York, N.Y.)|June 3, 2008
Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful?Ludwig Rinnab, Stefanie V Schütz, Jeannine Diesch, et al.
World Journal of Urology|February 24, 2009
[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomyLudwig Rinnab, Joerg Simon, Richard E Hautmann, et al.
World Journal of Urology|July 6, 2012
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancerThomas Schnoeller, Florian Jentzmik, Ludwig Rinnab, et al.
The Prostate|October 12, 2007
Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53Alexandra Prowald, Marcus V Cronauer, Christoph von Klot, et al.
BJU International|September 8, 2007
Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancerLudwig Rinnab, Felix M Mottaghy, Norbert M Blumstein, et al.
Urologia Internationalis|September 2, 2008
[11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective studyLudwig Rinnab, Felix M Mottaghy, Joerg Simon, et al.
Neoplasia (New York, N.Y.)|September 3, 2009
RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer diseaseKilian M Gust, Matthias D Hofer, Sven R Perner, et al.
Pageof 2